GSK Ojjaara approved in Canada for treatment of myelofibrosis in adults who have moderate to severe anemia Ruchika Sharma14 Nov 2024 1:15 PM ISTMississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or...
GSK Omjjara gets European Commission marketing authorisation Ruchika Sharma29 Jan 2024 4:45 PM ISTLondon: GSK plc has announced the European Commission has granted marketing authorisation for Omjjara (momelotinib), a once-a-day, oral JAK1/JAK2...
GSK gets positive EMA Committee opinion recommending Momelotinib for myelofibrosis patients with anaemia Ruchika Sharma15 Nov 2023 2:30 PM ISTLondon: GSK plc has announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive...
Momelotinib receives FDA approval for patients of myelofibrosis with anaemia Dr. Kamal Kant Kohli19 Sept 2023 8:00 PM ISTUSA: JAK inhibitor momelotinib (Ojjaara) has received approval from the US Food and Drug Administration (FDA) as the first therapy specifically for...
Medical Bulletin 19/September/2023 Isra Zaman19 Sept 2023 3:15 PM ISTHere are the top medical news of the day:Researchers uncover surprising side effects of common diabetes drug MetforminMetformin, a well-established...
FDA approves JAK inhibitor Momelotinib for Myelofibrosis in Anemic adults Isra Zaman19 Sept 2023 9:30 AM ISTThe US Food and Drug Administration (FDA) has approved momelotinib for the treatment of intermediate or high-risk myelofibrosis, including primary...
GSK gets USFDA nod for bone marrow cancer therapy Ojjaara Ruchika Sharma16 Sept 2023 11:54 AM ISTOjjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor.
GSK regulatory submission for myelofibrosis medicine momelotinib accepted for review by Japanese regulator Ruchika Sharma12 Sept 2023 11:29 AM ISTLondon: GSK plc has announced that the Ministry of Health, Labour and Welfare (MHLW), Japan, has accepted for review a new drug application (NDA) for...
USFDA extends review period of GSK Momelotinib by three months Ruchika Sharma17 Jun 2023 10:00 AM ISTLondon: GSK plc has announced that the US Food and Drug Administration (FDA) has extended the review period of the new drug application (NDA) for...
Targeted therapy momelotinib significantly improves symptoms and anemia in patients with myelofibrosis Dr. Kamal Kant Kohli9 Feb 2023 9:30 AM ISTPatients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated...
EMA validates marketing authorization application for blood cancer oral treatment Momelotinib: GSK Ruchika Sharma5 Dec 2022 10:30 AM ISTMyelofibrosis is a rare blood cancer that results from dysregulated JAK-signal transducer and activator of transcription protein signalling and is...
GSK new drug application for Myelofibrosis treatment Momelotinib accepted by USFDA Ruchika Sharma19 Aug 2022 2:00 PM ISTNew Delhi: GSK plc has announced that the US Food and Drug Administration (USFDA) has accepted the New Drug Application (NDA) for momelotinib, a...
